Evidence map›Paper›PMID 40868217›Full record

ReviewBiomedicines2025

Glioblastoma: From Pathophysiology to Novel Therapeutic Approaches.

Anatevka Ribeiro, Gianna Fote, Alexander Himstead, Michelle Zheng, Emma Elliott, Sara Mae Smith, Jerry Lou, Carlen A Yuen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomedicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. CAR-T cells immunotherapy in the treatment of glioblastoma.Cancer immunology, immunotherapy : CII · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Anatevka RibeiroDepartment of Neurology, Division of Neuro-Oncology, University of California, Irvine, CA 92697, USA.ORCID 0009-0001-6860-4076
Gianna FoteChao Family Comprehensive Cancer Center, University of California, Irvine, CA 92697, USA.
Alexander HimsteadChao Family Comprehensive Cancer Center, University of California, Irvine, CA 92697, USA.ORCID 0000-0001-9244-700X
Michelle ZhengUC Irvine Charlie Dunlop School of Biological Sciences, University of California, Irvine, CA 92697, USA.
Emma ElliottDepartment of Psychology, University of California, San Diego, La Jolla, CA 92093, USA.ORCID 0009-0005-9153-727X
Sara Mae SmithChao Family Comprehensive Cancer Center, University of California, Irvine, CA 92697, USA.
Jerry LouChao Family Comprehensive Cancer Center, University of California, Irvine, CA 92697, USA.ORCID 0009-0009-4241-8994
Carlen A YuenDepartment of Neurology, Division of Neuro-Oncology, University of California, Irvine, CA 92697, USA.ORCID 0000-0003-1950-8819

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor. Despite the current standard of care therapy, including maximal surgical resection, chemoradiation, and tumor-treating fields, prognosis remains poor. Therapeutic failure is driven by an immunosuppressive tumor microenvironment, poor drug penetration across the blood-brain barrier, and robust resistance mechanisms. Epigenetic alterations further compound treatment resistance by enhancing DNA repair and promoting survival pathways. Molecular profiling has identified key prognostic and predictive biomarkers. Gene expression analyses have delineated GBM subtypes, each with distinct molecular features and therapeutic vulnerabilities that hinder successful clinical translation. This review integrates the pathophysiological, diagnostic, and therapeutic landscape of GBM to inform of future strategies for improved patient outcomes.

Indexed as

chimeric antigen receptor (CAR) T-cell therapyGammaTile®glioblastomaimmunotherapylaser interstitial thermal therapy (LITT)theranosticsvaccine

Identifiers

PMID40868217
PMCPMC12384051

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.